Synthesis of two non-peptidyl GnRH receptor antagonists via [14C]carbonylation

Unlocking full and fast conversion in photocatalytic carbon dioxide reduction for applications in radio-carbonylation

Harvesting sunlight to drive carbon dioxide (CO₂) valorisation represents an ideal concept to support a sustainable and carbon-neutral economy. While the photochemical reduction of CO₂ to carbon monoxide (CO) has emerged as a hot research topic, the full CO₂-to-CO conversion remains an often-overlooked criterion that prevents a productive and direct valorisation of CO into high-value-added chemicals. Herein, we report a photocatalytic process that unlocks full and fast CO₂-to-CO conversion (<10 min) and its straightforward valorisation into human health related field of radiochemistry with carbon isotopes. Guided by reaction-model-based kinetic simulations to rationalize reaction optimisations, this manifold opens new opportunities for the direct access to ¹¹C- and ¹⁴C-labeled pharmaceuticals from their primary isotopic sources [¹¹C]CO₂ and [¹⁴C]CO₂.

Late-Stage Carbon-14 Labeling and Isotope Exchange: Emerging Opportunities and Future Challenges

Carbon-14 (¹⁴C) is a gold standard technology routinely utilized in pharmaceutical and agrochemical industries for tracking synthetic organic molecules and providing their metabolic and safety profiles. While the state of the art has been dominated for decades by traditional multistep synthetic approaches, the recent emergence of late-stage carbon isotope labeling has provided new avenues to rapidly access carbon-14-labeled biologically relevant compounds. In particular, the development of carbon isotope exchange has represented a fundamental paradigm change, opening the way to unexplored synthetic transformations. In this Perspective, we discuss the recent developments in the field with a critical assessment of the literature. We subsequently discuss research directions and future challenges within this rapidly evolving field.

A targeted delivery strategy for the development of potent trypanocides

A new drug delivery strategy was investigated for the development of potent anti-parasitic compounds against Trypanosoma brucei, the causative agent of African sleeping sickness. Thus, potent in vitro hexokinase inhibitors were rendered cytotoxic by appending a tripeptide peroxosomal targeting sequence that facilitated delivery of the molecular cargo to the appropriate organelle in the parasite.